[go: up one dir, main page]

CA2387542A1 - Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation - Google Patents

Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation Download PDF

Info

Publication number
CA2387542A1
CA2387542A1 CA002387542A CA2387542A CA2387542A1 CA 2387542 A1 CA2387542 A1 CA 2387542A1 CA 002387542 A CA002387542 A CA 002387542A CA 2387542 A CA2387542 A CA 2387542A CA 2387542 A1 CA2387542 A1 CA 2387542A1
Authority
CA
Canada
Prior art keywords
mesenchymal stem
recipient
transplant
immune response
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002387542A
Other languages
French (fr)
Other versions
CA2387542C (en
Inventor
Kevin R. Mcintosh
Joseph D. Mosca
Elena N. Klyushnenkova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387542A1 publication Critical patent/CA2387542A1/en
Application granted granted Critical
Publication of CA2387542C publication Critical patent/CA2387542C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective t o reduce or inhibit host rejection of the transplant. The mesenchymal stem cel ls can be administered before, at the same time as, or after the transplant. Al so disclosed is a method of inducing a reduced immune response against a host b y foreign tissue, i.e., graft versus host disease, by treatment with mesenchym al stem cells.

Claims (41)

1. A method for reducing an immune response against an alloantigen, comprising contacting immune effector cells with a supernatant from a mesenchymal stem cell culture in an amount effective to reduce the immune response.
2. The method of claim 1 wherein the effector cells are T cells.
3. A method for preventing or reducing reactivation of activated T cells comprising contacting T cells that have been previously activated by an alloantigen with a supernatant from a mesenchymal stem cell culture in an amount effective to suppress re-stimulation of said activated T cells.
4. A method of reducing an immune response to a donor transplant, comprising treating the recipient with a supernatant from a mesenchymal stem cell culture in an amount effective to reduce an immune response in the recipient to the transplant.
5. The method of claim 4 wherein the mesenchymal stem cells are autologous to the recipient.
6. The method of claim 4 wherein the mesenchymal stem cells are allogeneic to the recipient.
7. The method of claim 6 wherein the mesenchymal stem cells are obtained from the donor of the transplant.
8. The method of claim 4 wherein the mesenchymal stem cells are allogeneic to both the donor of the transplant and the recipient.
9. The method of claim 4 wherein the mesenchymal stem cells are xenogeneic to both the donor of the transplant and the recipient.
10. The method of claim 4 wherein the transplant is skin.
11. The method of claim 4 wherein the supernatant is administered to the recipient prior to administration of the transplant.
12. The method of claim 4 wherein the supernatant is administered concurrently with administration of the transplant.
13. The method of claim 4 wherein the supernatant is administered as a part of the transplant.
14. The method of claim 4 wherein the supernatant is administered after the transplant.
15. The method of claim 4 wherein the supernatant is administered to the transplant recipient to treat rejection of the transplant by the recipient.
16. The method of claim 4 further comprising administering to the recipient immunosuppressive agents.
17. The method of claim 4 wherein the transplant is a solid organ.
18. The method of claim 17 wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.
19. A method of treating a transplant recipient for graft versus host disease, comprising treating the recipient of a donor transplant with a supernatant from a mesenchymal stem cell culture in an amount effective to reduce an immune response against the recipient by the transplant.
20. The method of claim 19 wherein the mesenchymal stem cells are autologous to the recipient.
21. The method of claim 19 wherein the mesenchymal stem cells are autologous to the donor transplant.
22. The method of claim 19 wherein the mesenchymal stem cells are allogeneic to both the donor and recipient.
23. The method of claim 19 further comprising administering to the recipient immunosuppressive agents.
24. A composition for reducing an adverse immune response against a donor transplant, comprising a supernatant from a mesenchymal stem cell culture in an amount effective to inhibit or reduce an adverse immune response against a donor transplant, and a pharmaceutical carrier.
25. The composition of claim 24 wherein the mesenchymal stem cells are autologous to the recipient.
26. The composition of claim 24 wherein the mesenchymal stem cells are autologous to the donor.
27. The composition of claim 24 wherein the mesenchymal stem cells are allogeneic to both the recipient and the donor.
28. The composition of claim 24 wherein the mesenchymal stem cells are xenogeneic to both the recipient and the donor.
29. A composition for reducing an adverse immune response against a graft recipient caused by a graft, comprising a supernatant from a mesenchymal stem cell culture in an amount effective to reduce the adverse immune response against the graft recipient caused by the graft, and a pharmaceutical carrier.
30. The composition of claim 29 wherein the mesenchymal stem cells are autologous to the recipient.
31. The composition of claim 29 wherein the mesenchymal stem cells are autologous to the donor.
32. The composition of claim 29 wherein the mesenchymal stem cells are allogeneic to both the recipient and the donor.
33. The composition of claim 29 wherein the mesenchymal stem cells are xenogeneic to both the recipient and the donor.
34. The process of Claim 1 wherein the supernatant is obtained from mesenchymal stem cells co-cultured with T cells undergoing a mixed lymphocyte reaction.
35. A method for reducing an immune response against an alloantigen, comprising contacting immune effector cells with xenogeneic mesenchymal stem cells in an amount effective to reduce the immune response.
36. A method for reducing an immune response of effector cells against an alloantigen, comprising contacting effector cells with a supernatant of mesenchymal stem cells in an amount effective to reduce an immune response against an alloantigen whereby said effector cells upon contact with an alloantigen have a reduced immune response against said alloantigen.
37. The method of claim 36 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.
38. The method of claim 36 wherein said immune response to be reduced is an in vitro immune response.
39. The method of claim 36 wherein said immune response to be reduced is an in vivo immune response.
40. The method of claim 36 wherein said immune response to be reduced is an immune response to a donor transplant.
41. The method of claim 40 wherein said donor transplant is a xenogeneic donor transplant.
CA2387542A 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation Expired - Lifetime CA2387542C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/427,333 1999-10-26
US09/427,333 US6368636B1 (en) 1998-03-18 1999-10-26 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PCT/US2000/029815 WO2001032189A1 (en) 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Publications (2)

Publication Number Publication Date
CA2387542A1 true CA2387542A1 (en) 2001-05-10
CA2387542C CA2387542C (en) 2012-01-24

Family

ID=23694416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2387542A Expired - Lifetime CA2387542C (en) 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Country Status (10)

Country Link
US (2) US6368636B1 (en)
EP (2) EP1223956B1 (en)
JP (1) JP2004506598A (en)
AT (1) ATE482712T1 (en)
AU (1) AU782064B2 (en)
CA (1) CA2387542C (en)
DE (1) DE60045034D1 (en)
ES (1) ES2351203T3 (en)
PT (1) PT1223956E (en)
WO (1) WO2001032189A1 (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4441115B2 (en) * 1998-03-13 2010-03-31 オシリス セラピューティクス，インコーポレイテッド Methods and uses of human non-self mesenchymal stem cells
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
US8062675B2 (en) * 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU5340001A (en) * 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
AU3929402A (en) * 2000-11-22 2002-06-11 Geron Corp Tolerizing allografts of pluripotent stem cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2305795B1 (en) * 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2002243980B2 (en) 2001-02-14 2007-08-23 Robert J. Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
WO2003024462A1 (en) * 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
EP1487463A2 (en) * 2002-03-02 2004-12-22 Board Of Regents The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
JP4808961B2 (en) * 2002-06-04 2011-11-02 オフィス オブ テクノロジー ライセンシング スタンフォード ユニバーシティ Device for rapidly aspirating and collecting body tissue from an encapsulated body space
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
WO2004047860A2 (en) * 2002-11-28 2004-06-10 Genethor Gmbh Cells not presenting antigen for suppressing pathological immune reactions
CA2809195C (en) * 2003-04-01 2014-05-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
TR201901268T4 (en) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mesenchymal stem cells and their uses.
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
CN101080486B (en) * 2004-04-23 2012-05-16 佰欧益股份有限公司 Multi-lineage progenitor cells
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2006031539A2 (en) * 2004-09-10 2006-03-23 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation
KR101598947B1 (en) 2004-09-24 2016-03-08 메소블라스트, 아이엔씨. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
WO2006076374A1 (en) * 2005-01-11 2006-07-20 Cognate Therapeutics, Inc. Bone marrow stromal cells for immunoprotection of transplanted neural stem cells
US20080241112A1 (en) * 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
WO2008020815A1 (en) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
DK1926813T4 (en) * 2005-09-23 2019-08-19 Tigenix S A U Cell populations with immunoregulatory activity, isolation method and applications
US20070082328A1 (en) * 2005-09-27 2007-04-12 Donnie Rudd Rotatable time varying electromagnetic force bioreactor and method of using the same
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
CA2893204C (en) 2006-01-13 2016-11-29 Alla Danilkovitch Mesenchymal stem cells expressing tnf-.alpha. receptors
NZ744465A (en) 2006-01-23 2023-04-28 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
WO2007121443A2 (en) * 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
PT2772535T (en) 2006-05-31 2022-07-04 Childrens Medical Center Abc5 positive mesenchymal stem cells as immunomodulators
AU2007258514A1 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2465514A1 (en) * 2006-11-03 2012-06-20 Aastrom Biosciences, Inc. Mixed Cell Populations For Tissue Repair And Separation Technique For Cell Processing
PL2120977T3 (en) * 2007-02-12 2013-12-31 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
WO2008137115A1 (en) * 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
CN101835891A (en) * 2007-06-15 2010-09-15 加内特生物治疗学股份有限公司 Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US8263065B2 (en) 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
KR20100076031A (en) * 2007-10-17 2010-07-05 티엑셀 Tr1 cells, mesenchymal stem cells and uses thereof
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
US9011840B2 (en) * 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2009134429A2 (en) * 2008-05-02 2009-11-05 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
EP2294187A2 (en) * 2008-05-21 2011-03-16 BioE LLC Differentiation of multi-lineage progenitor cells to pancreatic cells
DK2329012T3 (en) * 2008-08-20 2020-08-24 Celularity Inc Treatment of stroke using isolated placental cells
EP3172963B1 (en) 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
DK2331109T3 (en) 2008-08-22 2013-09-08 Anthrogenesis Corp METHODS AND COMPOSITIONS FOR TREATING BONE JOFFECTS WITH PLACENTAL CELL POPULATIONS
ES2796111T3 (en) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Therapeutic methods related to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
RU2562154C2 (en) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Amniotic adhesive cells
AU2009316376B2 (en) * 2008-11-21 2015-08-20 Celularity Inc. Treatment of diseases, disorders or conditions of the lung using placental cells
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
KR20120115602A (en) * 2010-01-26 2012-10-18 안트로제네시스 코포레이션 Treatment of bone-related cancers using placental stem cells
PT2556145T (en) 2010-04-07 2016-10-25 Anthrogenesis Corp Angiogenesis using placental stem cells
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR101203954B1 (en) 2010-04-15 2012-11-22 서울대학교산학협력단 Composition for immunoregulation comprising endothelial-like mesenchymal stem cell
EP2568991B3 (en) 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
KR20230096132A (en) 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 Methods of generating natural killer cells
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150283180A1 (en) * 2011-11-04 2015-10-08 The Texas A& M University System Prevention and Treatment of Transplant Rejection with Mesenchymal Stem Cells and/or TSG-6 Protein
JP2016506968A (en) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション Placenta-derived natural killer cells
DK2964238T3 (en) 2013-02-19 2021-03-22 Childrens Medical Center ABCB5 (+) STEM CELLS FOR TREATING OCULAR DISEASE
EP3795159A1 (en) * 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
KR102319899B1 (en) 2013-05-10 2021-11-01 칠드런'즈 메디컬 센터 코포레이션 Wound healing and tissue engineering
WO2014189071A1 (en) * 2013-05-22 2014-11-27 独立行政法人国立精神・神経医療研究センター Stem cells for transplantation and manufacturing method therefor
WO2015023147A1 (en) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 Mtor/stat3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders
KR101723265B1 (en) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 Mesenchymal stem cells treated mTOR/STAT3 signaling inhibitor having immuno-modulating activity and cell therapeutic agent for preventing or treating immune disease
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
CN106232800B (en) 2014-03-25 2020-07-03 泰尔茂比司特公司 Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
RU2644650C2 (en) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Stem cell material and method for its reception
US20160287752A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component and method of forming same
CN113106053A (en) * 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 Therapeutic pooled apoptotic cell preparation and uses thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3397172B1 (en) 2016-02-01 2025-10-01 Regenmed Systems, Inc. Cannula for tissue disruption
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN109415696A (en) 2016-05-25 2019-03-01 泰尔茂比司特公司 Cell amplification
RU2708329C2 (en) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Stem cell material, compositions and methods of use
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
CN107454845A (en) * 2017-06-13 2017-12-08 广州赛莱拉干细胞科技股份有限公司 Stem cell composition for preventing and treating diabetic foot, application thereof, and stem cell preparation
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12448461B2 (en) 2018-04-25 2025-10-21 Children's Medical Center Corporation ABCB5 ligands and substrates
JP7705950B2 (en) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド How to grow cells
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
PT118103A (en) 2022-07-13 2024-01-15 Univ Aveiro BIOMATERIAL FOR IMMUNOMODULATION, PRODUCTION PROCESS AND ITS APPLICATIONS
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
DE69910362T2 (en) * 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. APPLICATION OF THE MESENCHYMAL STEM CELLS AS IMMUNE SUPPRESSIVA
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CA2490682A1 (en) 2004-12-16 2006-06-16 Ibm Canada Limited - Ibm Canada Limitee Method and system for advanced downloadings of urls for web navigation
TW200819387A (en) 2006-10-19 2008-05-01 Univ Yuan Ze Micro-reacting device having a micro-channel flow-guiding block

Also Published As

Publication number Publication date
EP2269616A3 (en) 2012-06-27
DE60045034D1 (en) 2010-11-11
ES2351203T3 (en) 2011-02-01
ATE482712T1 (en) 2010-10-15
WO2001032189A9 (en) 2002-07-04
CA2387542C (en) 2012-01-24
EP2269616A2 (en) 2011-01-05
JP2004506598A (en) 2004-03-04
US6368636B1 (en) 2002-04-09
AU782064B2 (en) 2005-06-30
EP1223956A1 (en) 2002-07-24
EP1223956B1 (en) 2010-09-29
PT1223956E (en) 2010-12-06
AU1244501A (en) 2001-05-14
US20020085996A1 (en) 2002-07-04
US6875430B2 (en) 2005-04-05
WO2001032189A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
Gamble et al. The journey of islet cell transplantation and future development
US6685936B2 (en) Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
JP6548714B2 (en) Methods for treating radiation or chemical injury
US20170157291A1 (en) Tissue transplant compositions and methods for use
EP2078073B1 (en) Kidney-derived cells and methods of use in tissue repair and regeneration
Burra et al. Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury
JP2002506831A5 (en)
KR101578591B1 (en) Cell Therapy Composition for Preventing or Treating Immune Disease Comprising Mesenchymal Stem Cells and Immunoregulatory T-cells as active ingredient
JP2004506598A5 (en)
Navsaria et al. Culturing skin in vitro for wound therapy
JP2003511398A5 (en)
Baiguera et al. Mesenchymal stromal cells for tissue‐engineered tissue and organ replacements
RS53210B (en) IMMUNOMODULATION USING PLACENTA CELL CELLS
JP2002529508A5 (en) Compositions comprising fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation and uses thereof
Casiraghi et al. Mesenchymal stromal cells to promote kidney transplantation tolerance
Gao et al. The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease
WO2009114860A2 (en) Activated mesenchymal stem cells for the prevention and repair of inflammatory states
Gurudutta et al. Stem cell therapy: a novel & futuristic treatment modality for disaster injuries
BRPI0620523A2 (en) method of increasing implant potential and cell attraction, method of preparing cells for transplantation in a subject, cell population and pharmaceutical composition
Khodadadi et al. Cell therapy in burn repair
US9232784B2 (en) Methods and compositions to modify the immunogenicity of a vascularized organ or tissue
Anwar et al. Therapeutic potential of umbilical cord stem cells for liver regeneration
Lei et al. Clinical trials with stem cell-derived insulin-producing cells
Schechter et al. Suppressor cells prevent host resistance to tumor growth

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201026